The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Systemic side effects of eye drops: a pharmacokinetic perspective
Open accessAbstract
When administering eye drops, even when completely correctly applied, several routes of absorption are possible and excess amounts can sometimes cause an unwanted systemic bioavailability of the drops when not completely absorbed into the eye. Furthermore, the concentration of active ingredients in such medicinal preparations is usually very high, so that despite the correct application of the recommended dose, considerable amounts may be absorbed in an unwanted manner through various routes. Children are subject to a much higher risk of systemic side effects because ocular dosing is not weight adjusted and physiological development (eg, liver status) differs from that of adults. There is a lack of information about pediatric dosing in the current literature. This review summarizes the most important clinically relevant systemic side effects that may occur during ophthalmic eye treatments. In this review, we discuss general pharmacokinetic considerations as well as the advantages, disadvantages, and consequences of administering drugs from some important drug groups to the eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye
Prausnitz, M. R., & Noonan, J. S. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js9802594 · Cited by 627
Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., & Cresteil, T. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00625.x · Cited by 539
Developmental Pharmacokinetics in Pediatric Populations
Lu, H., & Rosenbaum, S. (2014) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-19.4.262 · Cited by 358
Ocular absorption following topical delivery
Järvinen, K., Järvinen, T., & Urtti, A. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00010-5 · Cited by 358
Developmental Expression of Human Hepatic CYP2C9 and CYP2C19
Koukouritaki, S. B., Manro, J. R., Marsh, S. A., Stevens, J. C., Rettie, A. E., McCarver, D. G., & Hines, R. N. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060137 · Cited by 325
Cyclodextrins in ophthalmic drug delivery
Loftssona, T. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00055-6 · Cited by 305
Bashshur, Z. F., Bazarbachi, A., Schakal, A., Haddad, Z. A., El Haibi, C. P., & Noureddin, B. N. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.02.037 · Cited by 305
Cell culture models of the ocular barriers
Hornof, M., Toropainen, E., & Urtti, A. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.01.009 · Cited by 300
Ontogeny of human hepatic cytochromes P450
Hines, R. N. (2007) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20179 · Cited by 276
Vieira, I., Sonnier, M., & Cresteil, T. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0476z.x · Cited by 265
Minimizing systemic absorption of topically administered ophthalmic drugs
Urtti, A., & Salminen, L. (1993) · Survey of Ophthalmology · doi:10.1016/0039-6257(93)90141-s · Cited by 265
Safety evaluation of ocular drug delivery formulations: Techniques and practical considerations
Short, B. G. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310955 · Cited by 244
Formulations for children: problems and solutions
Batchelor, H. K., & Marriott, J. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12268 · Cited by 231
Delayed ontogenesis of CYP1A2 in the human liver
Sonnier, M., & Cresteil, T. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510893.x · Cited by 231
Expression of CYP2D6 in developing human liver
TRELUYER, J., JACQZ‐AIGRAIN, E., ALVAREZ, F., & CRESTEIL, T. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16411.x · Cited by 212
Maurice, D. M., & Mishima, S. (1984) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-69222-2_2 · Cited by 208
Silver, L. H. (1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00095-6 · Cited by 191
Treluyer, J.-M., Gueret, G., Cheron, G., Sonnier, M., & Cresteil, T. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00002 · Cited by 178
Developmental Changes in Human Liver CYP2D6 Expression
Stevens, J. C., Marsh, S. A., Zaya, M. J., Regina, K. J., Divakaran, K., Le, M., & Hines, R. N. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021873 · Cited by 164
Advanced drug delivery and targeting technologies for the ocular diseases
Barar, J., Aghanejad, A., Fathi, M., & Omidi, Y. (2016) · Bioimpacts · doi:10.15171/bi.2016.07 · Cited by 155
Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Vadlapudi, A. D., Vadlapatla, R. K., & Mitra, A. K. (2012) · Current Drug Targets · doi:10.2174/138945012800675650 · Cited by 130
Dafflon, M. L., Tran, V. T., Guex‐Crosier, Y., & Herbort, C. P. (1999) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s004170050235 · Cited by 127
Dosing in neonates: special considerations in physiology and trial design
Ku, L., & Smith, P. B. (2014) · Pediatric Research · doi:10.1038/pr.2014.143 · Cited by 126
Latanoprost in the treatment of glaucoma
Stolz, J., & Alm, A. (2014) · Clinical ophthalmology · doi:10.2147/opth.s59162 · Cited by 124
Walsh, J., Bickmann, D., Breitkreutz, J., & Chariot-Goulet, M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.048 · Cited by 114
Castillo, M., SCOTT, N. W., Mustafa, M. Z., Mustafa, M. S., & Azuara‐Blanco, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009566.pub2 · Cited by 94
Xu, X., Al-Ghabeish, M., Rahman, Z., Krishnaiah, Y. S. R., Yerlikaya, F., Yang, Y., Manda, P., Hunt, R. L., & Khan, M. A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.07.066 · Cited by 77
Özerdem, U., Levi, L., Cheng, L., Song, M., Scher, C. A., & Freeman, W. R. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00501-8 · Cited by 74
Hosoya, K., Makihara, A., Tsujikawa, Y., Yoneyama, D., Mori, S., Terasaki, T., Akanuma, S., Tomi, M., & Tachikawa, M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146381 · Cited by 67
Asthma Caused by Topical Application of Ketorolac
Sitenga, G. L., Ing, E. B., Dellen, R. G. V., et al. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30591-5 · Cited by 63
Levin, D. S., Han, D. P., Dev, S., et al. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01372-1 · Cited by 57
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Djebli, N., Khier, S., Griguer, F., Coutant, A.-L., Tavernier, A., Fabre, G., Leriche, C., & Fabre, D. (2016) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-016-0319-4 · Cited by 49
Topical Corticosteroid Therapy and Pituitary-Adrenal Function
Krupin, T., Mandell, A. I., Podos, S. M., & Becker, B. (1976) · Archives of Ophthalmology · doi:10.1001/archopht.1976.03910030459003 · Cited by 42
Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery
Vadlapatla, R. K., Vadlapudi, A. D., Pal, D., & Mitra, A. K. (2014) · Current Drug Metabolism · doi:10.2174/1389200215666140926152459 · Cited by 31
Pescina, S., Govoni, P., Antopolsky, M. L., Murtomäki, L. S., Padula, C., Santi, P., & Nicoli, S. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24465 · Cited by 30
VITRECTOMY FOR ACCIDENTAL INTRAOCULAR STEROID INJECTION
Gopal, L., Bhende, M. P., & Sharma, T. (1995) · Retina · doi:10.1097/00006982-199515040-00005 · Cited by 21
Guedes, G. B., Karan, A. M., Mayer, H. R., & Shields, M. B. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0123 · Cited by 19
Roters, S., Aspacher, F., & Diestelhorst, M. (2010) · Ophthalmologica · doi:10.1159/000310711 · Cited by 15
Cushing syndrome after bilateral lensectomy
Scherrer, K. S., Weitz, M., Eisenack, J., et al. (2014) · European Journal of Pediatrics · doi:10.1007/s00431-014-2477-1 · Cited by 14
Optimal Use of Topical Agents for Allergic Conjunctivitis
Mösges, R., Hassan, H. A., & Wenzel, M. R. (1997) · BioDrugs · doi:10.2165/00063030-199708040-00002 · Cited by 4
Cited by
Than, A., Liu, C., Chang, H., Duong, P. K., Cheung, C. M. G., Xu, C., Wang, X., & Chen, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06981-w · Cited by 345
Nanocarriers for ocular drug delivery: current status and translational opportunity
Gorantla, S., Rapalli, V. K., Waghule, T., Singh, P. P., Dubey, S. K., Saha, R. N., & Singhvi, G. (2020) · RSC Advances · doi:10.1039/d0ra04971a · Cited by 313
Mun, J., Mok, J. W., Jeong, S., Cho, S., Joo, C.-K., & Hahn, S. K. (2019) · RSC Advances · doi:10.1039/c9ra02858g · Cited by 82
Metadata
- Authors
- Farkouh, A., Frigo, P., & Czejka, M.
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2016-12
- Volume
- Volume 10
- Pages
- 2433-2441
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- OpenAlex
- W2560124981
- Cited by
- 255
- References
- 42
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.